Aurobindo Receives Approval For Fosinopril Sodium, Hydrochlorothiazide Tablets

Aurobindo Pharma has received final approval for Fosinopril Sodium and Hydrochlorothiazide Tablets (USP 10/12.5mg and 20/12.5mg) from the FDA.

Fosinopril Sodium and Hydrochlorothiazide Tablets USP 10/12.5mg and 20/12.5mg are the generic equivalent to Monopril HCT Tablets 10/12.5mg and 20/12.5mg of Bristol Myers Squibb.

The Fosinopril Sodium and Hydrochlorothiazide Tablets are indicated for hypertension and fall under the Cardio Vascular System therapeutic segment.

Aurobindo manufactures generic pharmaceuticals and active pharmaceutical ingredients. The company’s product portfolio is spread over six therapeutic/product areas encompassing Antibiotics, Anti- Retrovirals, CVS, CNS, Gastroenterologicals, and Anti-Allergics, supported by an extensive R&D set-up. The company is headquartered at Hyderabad, India.